Recently Viewed
Clear AllValue Research Rating
Quality Score 
0/0
Growth Score
0/0
Valuation Score
0/0
Momentum Score
0/0
Today’s Range
52 Week Range
Liquidity
Market cap
₹11,828 Cr
Revenue (TTM)
₹1,159 Cr
Net Profit (TTM)
₹313 Cr
ROE
22.3 %
ROCE
29.6 %
P/E Ratio
37.8
P/B Ratio
6.3
Industry P/E
33.39
EV/EBITDA
24.3
Div. Yield
0.9 %
Debt to Equity
0
Book Value
₹180.8
EPS
₹30.1
Face value
1
Shares outstanding
104,616,204
CFO
₹1,330.38 Cr
EBITDA
₹2,721.03 Cr
Net Profit
₹1,913.56 Cr
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Concord Biotech
| -17.1 | -3.0 | -17.0 | -32.5 | -- | -- | -- |
|
BSE Healthcare
| -3.7 | -3.4 | -3.7 | 3.4 | 24.8 | 15.5 | 10.6 |
|
Company
|
2025
|
2024
|
|---|---|---|
|
Concord Biotech
| -37.4 | 49.4 |
|
BSE Small Cap
| -6.6 | 29.0 |
|
BSE Healthcare
| -3.3 | 43.1 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price (₹) | Market Cap (₹ Cr) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Concord Biotech
|
1,115.3 | 11,827.9 | 1,158.7 | 309.6 | 31.9 | 17.3 | 37.8 | 6.3 |
| 347.0 | 3,172.1 | 2,521.8 | 202.5 | 9.6 | 14.3 | 15.7 | 2.1 | |
| 929.0 | 11,353.1 | 2,512.3 | 543.7 | 28.3 | 19.3 | 20.9 | 3.6 | |
| 370.7 | 6,400.9 | 1,053.1 | 293.6 | 32.3 | 24.6 | 21.8 | 4.9 | |
| 1,471.2 | 28,551.2 | 8,850.1 | 894.8 | 15.2 | 19.8 | 32.8 | 5.7 | |
| 12,035.0 | 15,604.3 | 1,575.1 | 179.1 | 14.9 | 11.4 | 87.1 | 9.4 | |
| 1,827.8 | 3,077.8 | 673.7 | 202.6 | 17.6 | 19.4 | 15.2 | 5.3 | |
| 754.6 | 3,492.0 | 588.5 | 102.9 | 22.1 | 12.7 | 34.4 | 4.1 | |
| 600.5 | 6,822.1 | 502.0 | 138.7 | -- | 32.8 | 49.2 | 7.9 | |
| 137.0 | 3,570.8 | 7.1 | -274.7 | -4,008.3 | -140.4 | -- | 5.4 |
4 min read•By Vishal Goyal
Concord Biotech Limited, a biopharma company, engages in the research and development, manufacture, market, and sale of pharmaceutical products in India and internationally. The company provides fermentation based active pharmaceutical ingredients in... immunosuppressants, anti-bacterial, oncology, antifungal, and other therapeutic areas. It also offers tacrolimus, mycophenolate mofetil, mycophenolate sodium, cyclosporine, sirolimus, voclosporin, and pimecrolimus for immunosuppressants therapeutic segment; and temsirolimus, everolimus, romidepsin, doxorubicin, mitomycin, midostaurin, and dactinomycin for oncology therapeutic segment. In addition, the company provides mupirocin, mupirocin calcium, polymyxin B sulfate, fidaxomicin, vancomycin hydrochloride, and teicoplanin for anti-bacterial applications; anidulafungin, caspofungi, micafungin sodium, and nystatin for anti-fungal therapeutic segment; and lovastatin and pravastatin sodium for other applications. Further, it develops daptomycin for anti-infectives applications; and epirubicin, idarubicin, and pirarubicin for oncology therapeutic segment. Additionally, the company provides contract research and manufacturing services in the areas of fermentation and semi-synthesis products. Concord Biotech Limited was incorporated in 1984 and is based in Ahmedabad, India. Read more
Incorporated
1984
Chairman
Sudhir Vaid
Managing Director
Sudhir Vaid
Headquarters
Ahmedabad Dist, Gujarat
Website
Looking for more details about Concord Biotech Ltd’s IPO? Explore our IPO Details page.
Our rating system has guided millions of investors in the past 20 years.
The share price of Concord Biotech Ltd is ₹1,115.30 (NSE) and ₹1,116.00 (BSE) as of 19-Mar-2026 13:59 IST. Concord Biotech Ltd has given a return of -32.46% in the last 1 years.
The P/E ratio of Concord Biotech Ltd is 37.85 times as on 19-Mar-2026, a 13 premium to its peers’ median range of 33.39 times.
The P/B ratio of Concord Biotech Ltd is 6.25 times as on 19-Mar-2026, a 189 premium to its peers’ median range of 2.16 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
47.19
|
9.67
|
|
2024
|
51.68
|
10.43
|
|
2023
|
0.00
|
0.00
|
|
2022
|
0.00
|
0.00
|
|
2021
|
0.00
|
0.00
|
The 52-week high and low of Concord Biotech Ltd are Rs 2,150.40 and Rs 1,068.60 as of 19-Mar-2026.
Concord Biotech Ltd has a market capitalisation of ₹ 11,828 Cr as on 19-Mar-2026. As per SEBI classification, it is a Small Cap company.
Before investing in Concord Biotech Ltd, assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
₹-27.60
(
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.